:: Journal of the Preventive Veterinary Medicine ::
Journal Search Engine
Search Advanced Search Adode Reader(link)
Download PDF Export Citaion korean bibliography PMC previewer
ISSN : 2287-7991(Print)
ISSN : 2287-8009(Online)
Journal of the Preventive Veterinary Medicine Vol.42 No.2 pp.61-65
DOI : https://doi.org/10.13041/jpvm.2018.42.2.61

Anti-inflammatory activity of doxorubicin on lipopolysaccharide-induced hyperactivation of spleen cells

Ye-Ryoung Jang1,Hye-Rin Yoon1,Mi-Hyoung Kim2,Hong-Gu Joo1†
1Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, Jeju National University, Jeju 63243, Republic of Korea
2Department of Companion animal, Digital Seoul Culture Arts University, Seoul 03645, Republic of Korea
Corresponding Author. Hong-Gu Joo, Tel: +82-64-754-3379, Fax: +82-64-756-3354, E-mail: jooh@jejunu.ac.kr


Doxorubicin has been used to treating cancers, including breast cancer, bladder cancer, and acute lymphocytic leukemia, however, few studies have investigated its anti-inflammatory activity. In this study, we used mouse spleen cells treated with lipopolysaccharide (LPS), a representative inflammatory agent to investigate the effects of doxorubicin. Specially, we investigated the effects of doxorubicin on metabolic activity, cell size, cell death, and cytokine production of LPS-treated spleen cells. Doxorubicin significantly decreased the metabolic activity, even when applied at relatively low concentrations (1.6-8 ng/mL). To investigate the potential mechanism, we measured the mitochondrial membrane potential (MMP) of the LPS-treated spleen cells using Rhodamine 123. Doxorubicin decreased MMP and cell size, and induced cell death. Furthermore, doxorubicin suppressed the production of tumor necrosis factor (TNF)-alpha, a representative cytokine, in LPS-treated spleen cells. Taken together, doxorubicin decreased metabolic activity and the production of inflammatory cytokines, while increasing the death of LPS-induced hyperactivated spleen cells. This results will enable broader application of doxorubicin, as an anti-inflammatory agent, in clinical and research fields.